

Olanzapine-associated hypothermia: a case report of a rare event

Manuel Monti, Valeria Mommi, Maria Beatrice Forte, Francesco Paciullo, Francesca Francavilla, Francesco Borgognoni

Emergency Department, Local Health Unit Umbria 1, Assisi (PG), Italy

ABSTRACT

Hypothermia, a potentially fatal condition, is defined as a drop of the body temperature below 35°C. The most common cause of severe hypothermia is the environmental exposure to low-temperatures. Other causes include septicemia, diabetic ketoacidosis, trauma, acute spinal cord injury, prolonged cardiac arrest and hypothyroidism. The hypothermia is an infrequent, but previously documented, adverse effect of antipsychotic medications. A 83-year-old Italian woman was transported to the Emergency Room with a reduced level of consciousness, Glasgow coma scale 7. She was bradycardic (heart rate 42 bpm), 80/150 mmHg blood pressure and respiratory rate 26/min. Her physical examination was significant for an anal temperature of 31°C. Blood exam and chest X-ray were unremarkable. In her clinical history, she was suffering from generalized anxiety disorder for the last 2 years and was prescribed olanzapine 7.5 mg daily. In recent days, the patient experienced a cognitive impairment with heat intolerance and had been reduced the dose of olanzapine 5 mg daily. On the basis of the clinical findings, the patient's body temperature and blood exam, the diagnosis of olanzapine-associated hypothermia was made. The patient was gradually rewarmed with blankets and warm saline infusion and the olanzapine therapy was discontinued. She gradually regained consciousness after 18 h and, after 1 day, the patient's body temperature increased up to 37.8°C with an improvement of the neurological conditions. We reported about the case of a patient treated with stable doses of olanzapine for a long period of time that developed hypothermia, a potentially fatal complication. This case shows that it is important to consider every change in the patient behavior, e.g., the poor resistance to heat present in our patient, that should exhibit warning sign of hypothermia.

Introduction

Thermoregulation occurs in the preoptic area of the anterior hypothalamus and the hypothermia is defined as a state in which the body's mechanism for regulating the temperature is altered.¹

Hypothermia is defined as a decline in core temperature below 35°C. Hypothermia can be classified as mild (core body temperature: 32.0°C to <35.0°C),

moderate (28.0°C to <32.2°C), or severe (below 28.0°C).^{2,3}

The mechanisms that contribute to mortality depend on the metabolic changes. These modifications cause acidosis, changes in the plasma Ca²⁺, and the clearance of magnesium and potassium from the cells to the extracellular space. At the level of the heart, this causes a decreased depolarization of cardiac pacemaker cells with consequent bradycardia and ventricular arrhythmias.^{4,5}

Furthermore, hypothermia progressively reduces the metabolism of the central nervous system because there is a decrease in the consumption of oxygen that is linear with respect to the temperature reduction.⁵ In the absence of medical disorders that alter the temperature regulation control system, unintentional hypothermia is caused by environmental exposure.⁶ Secondary hypothermia results when a disease state interferes with thermoregulation through interference of any of the multiple pathways that maintain heat balance (such as a medical illness lowering the temperature set-point or a major trauma).⁷ Although hyperthermia is more commonly linked to antipsychotics, profound hypothermia may also occur.⁸

Correspondence: Manuel Monti, USL UMBRIA1 U.O. PS/118, via V. Muller 1, 06081 Assisi (PG), Italy.
E-mail: montimanuel@tiscali.it

Key words: Antipsychotics; hypothermia; medication effects; olanzapine.

Conflict of interest: the authors declare no potential conflict of interest.

Received for publication: 8 October 2017.
Revision received: 3 December 2017.
Accepted for publication: 29 January 2018.

This work is licensed under a Creative Commons Attribution NonCommercial 4.0 License (CC BY-NC 4.0).

©Copyright M. Monti et al., 2018
Licensee PAGEPress, Italy
Italian Journal of Medicine 2018; 12:67-69
doi:10.4081/ijm.2018.937

Case Report

An 83-year-old Italian woman was transported to the emergency room with a reduced level of con-

sciousness, Glasgow coma scale 7. She opened her eyes to verbal response, and she was able to localize pain. She was bradycardic (heart rate 42 bpm), her blood pressure was 80/150 mmHg and respiratory rate 26/min. The patient had normal heart and breath sounds. Abdomen, and musculoskeletal examinations were unremarkable. Her physical examination was significant for an anal temperature of 30.9°C. At the time of admission, the electrocardiogram showed sinus bradycardia with J waves. The thyroid-stimulating hormone level was 2.2 mU/L and free thyroxine level was 2.8 u/dL. Random and early morning cortisol levels were checked and also were within normal limits (Table 1).

Current medications at admission: omeprazole 20

mg once a day, hydrochlorothiazide/amiloride 25/5 mg once a day, acetylsalicylic acid 75 mg, alprazolam 0.25 mg twice daily, olanzapine 7.5 mg daily. She was a widow and lived with her daughter. In her clinical history, she was suffering from generalized anxiety disorder for the last 2 years and was prescribed olanzapine 7.5 mg daily for two years. On the days before the event, the patient experienced a cognitive impairment with heat intolerance and had been reduced the dose of olanzapine 5 mg daily. On the basis of the clinical findings, the patient's body temperature and electrocardiogram findings, the diagnosis of hypothermia was made (Figure 1). The patient did not have any risk factors for developing hypothermia except for the use of olanzapine.

Table 1. Patient's main serum chemistry values.

Laboratory data	Numerical value (SI units)	Normal range values
Hb	115 g/L	120-160 g/L
MCV	93.5 fL	81-99 fL
MCHC	350 g/L	330-370 g/L
PLT	1.75×10 ⁹ /L	130-400×10 ⁹ /L
WBC	9.1×10 ⁹ /L	4.8-10.8×10 ⁹ /L
TSH	2.2 mU/L	0.4-5.0 mU/L
Sodium	137 mEq/L	132-143 mEq/L
Potassium	4,4 mEq/L	3.5-5.8 mEq/L
Troponin I	0 µg/mL	<1.5 µg/mL
Free T4	10.2 pmol/L	8.5-15.2 pmol/L
C-reactive protein	6.7 mg/L	<5 mg/L
Creatinine	105 µmol/L	<115 µmol/L

Hb, hemoglobin; MCV, mean corpuscular volume; MCHC, mean corpuscular hemoglobin concentration; PLT, platelets; WBC, white blood cells; LDH, lactate dehydrogenase; TSH, thyroid-stimulating hormone; free T4, free thyroxine.




Figure 1. Electrocardiogram showing bradycardia and the presence of the J wave.

She was rewarmed gradually with warmed saline intravenous solutions, washing with warm fluids through nasogastric tube and urinary catheter, and external heating by thermal blanket. The olanzapine was discontinued. She gradually regained consciousness after 18 h. After clinical improvement, the patient's body temperature was 37.8°C and we witnessed an overall improvement of her neurological conditions.

Discussion

Hypothermia has long been a dangerous complication of antipsychotic drug therapy. The most common antipsychotic drug associated with hypothermia is risperidone.⁹ Olanzapine is an atypical antipsychotic drug. In normal conditions, dopaminergic and serotonin receptor activity, which decrease and increase body temperature, respectively, are balanced. Mainly, olanzapine has a higher affinity for 5-HT₂ serotonin receptors than D₂ dopamine receptors and this is responsible for a deterioration of this balance, and this increases the risk of developing hypothermia.^{10,11}

Also, olanzapine increases the concentrations of neurotensin.¹² Neurotensin is present at high concentrations in the hypothalamus and has been recognized as an important mediator of hypothermia. The increase of the neurotensin facilitates the development of hypothermia.¹²

Conclusions

Based on the findings in our patient and from the data from literature, we hypothesize that the patient developed hypothermia due to olanzapine.

This indicates that, when we are faced with a patient with hypothermia, a careful history should be done and we must consider antipsychotics a potential cause of hypothermia, particularly in the elderly with recent behavioral changes.

References

1. Kreuzer P, Landgrebe M, Wittmann M, et al. Hypothermia associated with antipsychotic drug use: a clinical case series and review of current literature. *J Clin Pharmacol* 2012;52:1090-7.
2. Vanden Hoek TL, Morrison LJ, Shuster M, et al. Part 12: Cardiac arrest in special situations. *Circulation* 2010;122:S829-61.
3. Lazar HL. The treatment of hypothermia. *N Engl J Med* 1997;337:1545-7.
4. Jeican II. The pathophysiological mechanisms of the onset of death through accidental hypothermia and the presentation of "The little match girl" case. *Clujul Med* 2014;87:54-60.
5. Kempainen RR, Brunette DD. The evaluation and management of accidental hypothermia. *Respir Care* 2004;49:192-205.
6. Wong KC. Physiology and pharmacology of hypothermia. *West J Med* 1983;138:227-32.
7. Søreide K. Clinical and translational aspects of hypothermia in major trauma patients: from pathophysiology to prevention, prognosis and potential preservation. *Injury* 2014;45:647-54.
8. Parris C, Mack JM, Cochiolo JA, et al. Hypothermia in 2 patients treated with atypical antipsychotic medication. *J Clin Psychiatry* 2001;62:61-3.
9. Schwaninger M, Weisbrod M, Schwab S, et al. Hypothermia induced by atypical neuroleptics. *Clin Neuropharmacol* 1998;21:344-6.
10. Rasnayake LR, Wimalarathne H, Jayapala RK, et al. An unusual case of hypothermia associated with therapeutic doses of olanzapine: a case report. *J Med Case Rep* 2011;5:189.
11. Kansagra A, Patel S, Wilcox SR. Prolonged hypothermia due to olanzapine in the setting of renal failure: a case report and review of the literature. *Ther Adv Psychopharmacol* 2013;3:335-9.
12. Sharma RP, Janicak PG, Bisette G, Nemeroff CB. CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder. *Am J Psychiatry* 1997;154:1019-21.